Abstract: A method and apparatus is provided to iteratively reconstruct a computed tomography (CT) image using a spatially-varying content-oriented regularization parameter, thereby achieving uniform statistical properties within respective organs/regions and different statistical properties (e.g., degree of smoothing and noise level) among the respective organs/regions. For example, less smoothing and sharper features/resolution can be applied within a lung region than within a soft-tissue region by using a smaller regularization parameter value in the lung region than in the soft-tissue region. This can be achieved, e.g., using a minimum intensity projection to suppress/eliminate sub-solid nodules in the lung region. The content-oriented regularization parameter can be generated by reconstructing an initial CT image, which is then segmented/classified according to organs and/or tissue type.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
June 16, 2020
Assignees:
CANON MEDICAL SYSTEMS CORPORATION, UNIVERSITY HEALTH NETWORK
Inventors:
Chung Chan, Zhou Yu, Jian Zhou, Patrik Rogalla, Bernice Hoppel, Kurt Walter Schultz
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
September 12, 2018
Date of Patent:
June 2, 2020
Assignees:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.
Type:
Application
Filed:
August 22, 2018
Publication date:
May 21, 2020
Applicants:
UNIVERSITY HEALTH NETWORK, THE HOSPITAL FOR SICK CHILDREN
Inventors:
Gordon KELLER, Shinichiro OGAWA, Anand GHANEKAR, Christine BEAR, Binita M. KAMATH, Mina OGAWA, James SURAPISITCHAT
Abstract: Methods for quantifying fluorescence and optical properties in a turbid medium such as tissue. Devices and systems suitable for the methods are also disclosed.
Type:
Application
Filed:
December 23, 2019
Publication date:
May 21, 2020
Applicant:
University Health Network
Inventors:
Anthony Taywon Kim, Brian Campbell WILSON
Abstract: Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
July 2, 2016
Date of Patent:
April 28, 2020
Assignees:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: Systems and methods for obtaining diagnostic data of a target are disclosed. The systems include an imaging device and a drape. The imaging device includes at least one excitation light source for fluorescent imaging, and an optical sensor configured to detect signals responsive to illumination of the target with the excitation light. The drape is configured to reduce ambient light surrounding the target during imaging.
Abstract: Various embodiments are described herein for a system and a method for treatment planning for providing ablative therapy to a patient. The treatment planning may involve segmenting images of the patient to define areas to receive treatment, defining trial parameters, simulating treatment of ablative therapy to the patient according to the trial parameters; analyzing a thermal dose distribution resulting from the simulated treatment to determine treatment effectiveness; determining when the treatment effectiveness meets a treatment effectiveness criteria; and providing an indication of the trial parameters when the treatment effectiveness meets the treatment effectiveness criteria.
Type:
Grant
Filed:
May 13, 2016
Date of Patent:
March 31, 2020
Assignees:
University Health Network, Sunnybrook Research Institute
Inventors:
Sean Davidson, Michael D. Sherar, Kieran Murphy, Claire McCann, Robert Weersink
Abstract: A Radio-Therapy (RT) system includes an integrated radiation source and a Magnetic Resonance Imaging (MRI) system that implements a method for providing a variable imaging Field Of View (FOV). The FOV can be tailored for various RT-specific applications such as, but not limited to, patient setup verification and real-time tumor tracking, for example, as well as for various imaging volumes of interest.
Type:
Grant
Filed:
July 29, 2013
Date of Patent:
March 24, 2020
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Teodor Marius Stanescu, David Anthony Jaffray
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Application
Filed:
September 26, 2019
Publication date:
March 19, 2020
Applicants:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
YUE LIU, TARLOCHAN S. NIJJAR, AVIJIT CHAKRABARTTY, JEFFREY N. HIGAKI
Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): (Formula (I)) wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
March 10, 2020
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
Type:
Grant
Filed:
October 9, 2018
Date of Patent:
February 25, 2020
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Application
Filed:
October 30, 2019
Publication date:
February 20, 2020
Applicants:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: Methods, devices and systems for quantifying fluorescence and optical properties in a turbid medium such as tissue are disclosed. One of the methods comprises: providing fluorescence emission and reflectance wavelengths detected from a target surface where each of the detected wavelengths is associated with a respective known distance between a respective excitation source giving rise to the respective detected wavelength and a detector detecting the respective detected wavelength; and calculating the optical properties based on the detected wavelengths and the respective known distances. The known distances may be predetermined to enable calculation of a desired range of values for the optical properties. The calculation of the optical properties may be based on a model of light interaction with the turbid medium where the model limits a range of calculated values for the optical properties.
Type:
Grant
Filed:
January 25, 2011
Date of Patent:
February 18, 2020
Assignee:
University Health Network
Inventors:
Anthony Taywon Kim, Brian Campbell Wilson
Abstract: Provided are methods for producing compositions comprising a population of cardiomyocytes enriched for or substantially devoid of sinoatrial node-like pacemaker cardiomyocytes (SANLCM) from human pluripotent stem cells (hPSCs), and methods of use thereof.
Abstract: The present invention is directed to methods and compositions for identifying targets for induction of self-tolerance and treatment of autoimmune disease.
Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
January 7, 2020
Assignees:
Regeneron Pharmaceuticals, Inc., University Health Network
Inventors:
Lisa Arleen Purcell, Sarah J. Higgins, Kevin C. Kain
Abstract: Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute myeloid leukemia (AML). The use of allogenic DNTs, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with graft-versus-host-disease, is also described.
Abstract: Described are various embodiments of an acoustic upper airway assessment system and method, and sleep apnea assessment system and method relying thereon. In one embodiment, a non-invasive method is described for assessing upper airway anatomy in a subject while breathing. This method comprises receiving as input at a hardware processor a digital signal representative of respiratory sounds generated by the subject while breathing; isolating digital respiratory sound segments from said digital signal; computationally extracting a designated spectral feature from each of said segments to characterize said respiratory sounds within each of said segments; automatically evaluating each said extracted spectral feature against a preset upper airway anatomy metric associated with said designated spectral feature to characterize a given upper airway anatomy measure in the subject while breathing; and outputting a sleep apnea severity indication based on said characterized upper airway anatomy measure.
Type:
Grant
Filed:
May 31, 2016
Date of Patent:
December 17, 2019
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Azadeh Yadollahi, Frank Rudzicz, Shumit Saha
Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
Type:
Grant
Filed:
June 23, 2016
Date of Patent:
December 10, 2019
Assignee:
University Health Network
Inventors:
Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang